Treatment and outcomes of primary urethral cancer
Asian J Surg. 2022 Feb 11:S1015-9584(22)00027-6. doi: 10.1016/j.asjsur.2022.01.014. Online ahead of print.NO ABSTRACTPMID:35165024 | DOI:10.1016/j.asjsur.2022.01.014 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - February 15, 2022 Category: Surgery Authors: Shujun Yang Shun Wan Duo Zheng Yongsheng Yin Weiping Li Panfeng Shang Source Type: research
Cancers, Vol. 14, Pages 845: Brachytherapy for the Conservative Treatment of Female Peri-Urethral Carcinoma
Conclusions: In this cohort of women with PUC undergoing BT, we observed an 80% probability of local control with acceptable morbidity. Though survival was poor, with high metastatic relapse probability, BT was useful to focally escalate the dose and optimize local control in the context of an organ sparing strategy. (Source: Cancers)
Source: Cancers - February 8, 2022 Category: Cancer & Oncology Authors: Micka ël Andraud Manon Kissel Manon Roger Sun Elie Rassy Sophie Espenel Samir Achkar Philippe Morice Christine Haie-Meder S ébastien Gouy Cyrus Chargari Tags: Article Source Type: research
A rare association in a patient with non-muscle invasive bladder cancer: ureteral fibroepithelial polyp and ipsilateral renal cell carcinoma: a case report
ConclusionsAlthough our patient had a bladder transitional cell carcinoma and a suspicious renal cell carcinoma mass of 15 mm in the ipsilateral kidney, the patient was safeguarded from unnecessary nephroureterectomy early on by cross-sectional and endoscopic imaging of the ureter. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - September 26, 2021 Category: General Medicine Source Type: research
The role of regional lymph node dissection in men with primary urethral carcinoma
(Source: World Journal of Urology)
Source: World Journal of Urology - September 24, 2021 Category: Urology & Nephrology Source Type: research
Urethral Masses
Urethral and periurethral masses in women include both benign and malignant entities that can be difficult to clinically differentiate. Primary urethral carcinoma is rare and the optimal treatment modality may vary depending on the stage at presentation. Because cancer-free survival is poor, clinicians shouldhave a high index of suspicion when evaluating a urethral mass. Some benign-appearing urethral masses may be safely observed. Surgical resection is an effective option that should be used based on patient preference and symptoms, and for suspicious lesions. (Source: Obstetrics and Gynecology Clinics)
Source: Obstetrics and Gynecology Clinics - August 18, 2021 Category: OBGYN Authors: Emily C. Serrell, Sarah E. McAchran Source Type: research
Primary urethral carcinoma: Results from a single center experience
Actas Urol Esp. 2021 Jul 28:S0210-4806(21)00096-6. doi: 10.1016/j.acuro.2020.10.014. Online ahead of print.ABSTRACTINTRODUCTION AND AIM OF THE STUDY: Primary urethral carcinoma (PUC) is a rare neoplastic disease arising in the urethra, without any evidence of a previous or synchronous carcinoma of the entire urinary tract. Since rare diseases are often incorrectly diagnosed and managed, the aim of this study was to analyze the experience of a single urology center in the treatment of PUC, focusing on neoplasms arising from the male anterior urethra.MATERIALS AND METHODS: Medical records of patients with neoplasms at the le...
Source: Actas Urologicas Espanolas - August 1, 2021 Category: Urology & Nephrology Authors: J F Calder ón Cortez A Territo M Fontana J M Gaya F Sanguedolce J Palou J Huguet A Breda Source Type: research
Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation
Primary urethral carcinoma (PUC) is a rare genitourinary malignancy with a relatively poor prognosis. The aim of this study was to examine the impact of surgery on survival of patients diagnosed with PUC. (Source: BMC Cancer)
Source: BMC Cancer - July 27, 2021 Category: Cancer & Oncology Authors: Jie Wu, Yu-Chen Wang, Wen-Jie Luo, Bo-Dai, Ding-Wei Ye and Yi-Ping Zhu Tags: Research article Source Type: research
Comprehensive genomic profiling of histologic subtypes of urethral carcinomas
CONCLUSIONS: Comprehensive genomic profiling reveals GA that may be predictive of both targeted and immunotherapy benefit in patients with advanced UrthCa and that could potentially be used in future adjuvant, neoadjuvant, and metastatic disease trials.PMID:34215504 | DOI:10.1016/j.urolonc.2020.12.021 (Source: Urologic Oncology)
Source: Urologic Oncology - July 3, 2021 Category: Urology & Nephrology Authors: Joseph Jacob Andrea Necchi Petros Grivas Michael Hughes Thomas Sanford Mehdi Mollapour Oleg Shapiro Ahmad Talal Ethan Sokol Jo-Anne Vergilio Jonathan Killian Douglas Lin Erik Williams Julie Tse Shakti Ramkissoon Eric Severson Amanda Hemmerich Naomi Fergus Source Type: research
Comprehensive genomic profiling of histologic subtypes of urethral carcinomas
CONCLUSIONS: Comprehensive genomic profiling reveals GA that may be predictive of both targeted and immunotherapy benefit in patients with advanced UrthCa and that could potentially be used in future adjuvant, neoadjuvant, and metastatic disease trials.PMID:34215504 | DOI:10.1016/j.urolonc.2020.12.021 (Source: Urologic Oncology)
Source: Urologic Oncology - July 3, 2021 Category: Urology & Nephrology Authors: Joseph Jacob Andrea Necchi Petros Grivas Michael Hughes Thomas Sanford Mehdi Mollapour Oleg Shapiro Ahmad Talal Ethan Sokol Jo-Anne Vergilio Jonathan Killian Douglas Lin Erik Williams Julie Tse Shakti Ramkissoon Eric Severson Amanda Hemmerich Naomi Fergus Source Type: research
